Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Mental Health Emerging Therapies topic
No spam. Unsubscribe anytime.
House committee advances pilot program for psychedelic‑assisted therapy with broad veteran and clinician support
Summary
Senate Bill 1042 to establish a mental‑health emerging therapies pilot program advanced after extensive testimony from veterans, clinicians and advocacy groups urging training, research and patient access for FDA‑designated breakthrough therapies.
A House Committee on Finance recommended passage Monday of Senate Bill 1042 SD1 HD1, the Mental Health Emerging Therapies pilot program, after a broad hearing that drew veterans, clinicians, researchers and nonprofit leaders.
The bill would create an authority and program framework to prepare for and implement supervised clinical trials, workforce training and patient access pilots for emerging therapies such as MDMA and psilocybin that have received FDA "breakthrough therapy" designations for certain conditions, supporters said.
Tia Hartsock, director of the Office of Wellness and Resilience, told the committee the office supports establishing a pathway and asked for amendments to allow greater timeline flexibility and authority to implement if federal approvals shift. "This measure creates a pathway for those in need to have access to innovative and life saving treatments," she said. Hartsock said the office and advocates were working on private funding opportunities to help stand up training and trial infrastructure.
Veterans and clinicians gave emotional testimony about treatment gaps. Retired Master Sergeant Joe Hudak, who testified that psychedelic‑assisted therapy “completely changed my life,” urged lawmakers to provide access for veterans with treatment‑resistant PTSD. Multiple veteran speakers and the Veteran Mental Health Leadership Coalition said the pilot could provide safe, supervised access and training that would otherwise be unavailable in the state.
Advocates emphasized workforce development, clinician training, public education and harm‑reduction strategies. Clarity Project pledged private philanthropic commitments and the testimony cited Connecticut and Texas as models where pilot programs included university partnerships and clinical trials to build workforce capacity ahead of wider regulatory approvals.
Committee action and next steps: the committee recommended passage of the bill with the appropriation set as a blank placeholder for conference negotiations; the Office of Wellness requested authority to extend timelines and to accept private and philanthropic funds to scale the program. The committee added technical amendments and moved the bill forward for conference to finalize appropriations and implementation details.
Ending: Supporters said the measure is intended to position Hawaii to responsibly deliver evidence‑based treatments if and when federal approvals expand access, while building clinician training and research capacity within the state.
